$25.93
0.54[2.13%]
At close: Apr 19
$25.93
0[0.00%]
After Hours: 7:59PM EDT
Pfizer Stock (NYSE:PFE), Analyst Ratings, Price Targets, Predictions
Pfizer Inc has a consensus price target of $40.54, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Cantor Fitzgerald, and Cantor Fitzgerald on April 18, 2024, April 15, 2024, and April 5, 2024. With an average price target of $45 between Cantor Fitzgerald, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 73.54% upside for Pfizer Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Argus Research
Guggenheim
TD Cowen
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Pfizer
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/15/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | PFE | Buy Now | Pfizer | $25.93 | — | Argus Research | David Toung | — | Downgrade | Buy → Hold | Get Alert |
| 03/04/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | PFE | Buy Now | Pfizer | $25.93 | 38.84% | Guggenheim | Vamil Divan | → $36 | Initiates | → Buy | Get Alert |
| 01/31/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/09/2024 | PFE | Buy Now | Pfizer | $25.93 | 73.54% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/04/2024 | PFE | Buy Now | Pfizer | $25.93 | 23.41% | TD Cowen | Steve Scala | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/14/2023 | PFE | Buy Now | Pfizer | $25.93 | 38.84% | Truist Securities | Robyn Karnauskas | $42 → $36 | Maintains | Buy | Get Alert |
| 12/14/2023 | PFE | Buy Now | Pfizer | $25.93 | 4.13% | UBS | Colin Bristow | $34 → $27 | Maintains | Neutral | Get Alert |
| 12/14/2023 | PFE | Buy Now | Pfizer | $25.93 | 7.98% | Barclays | Carter Gould | $34 → $28 | Maintains | Equal-Weight | Get Alert |
| 12/04/2023 | PFE | Buy Now | Pfizer | $25.93 | 61.97% | Truist Securities | Robyn Karnauskas | → $42 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | PFE | Buy Now | Pfizer | $25.93 | 189.24% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 11/01/2023 | PFE | Buy Now | Pfizer | $25.93 | 31.12% | Barclays | Carter Gould | $35 → $34 | Maintains | Equal-Weight | Get Alert |
| 11/01/2023 | PFE | Buy Now | Pfizer | $25.93 | 42.69% | Morgan Stanley | Terence Flynn | $39 → $37 | Maintains | Equal-Weight | Get Alert |
| 10/20/2023 | PFE | Buy Now | Pfizer | $25.93 | 31.12% | UBS | Colin Bristow | $36 → $34 | Assumes | Neutral → Neutral | Get Alert |
FAQ
What is the target price for Pfizer (PFE)?
The latest price target for Pfizer (NYSE: PFE) was reported by Cantor Fitzgerald on April 18, 2024. The analyst firm set a price target for $45.00 expecting PFE to rise to within 12 months (a possible 73.54% upside). 49 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pfizer (PFE)?
The latest analyst rating for Pfizer (NYSE: PFE) was provided by Cantor Fitzgerald, and Pfizer reiterated their overweight rating.
When was the last upgrade for Pfizer (PFE)?
The last upgrade for Pfizer Inc happened on October 16, 2023 when Jefferies raised their price target to $39. Jefferies previously had a hold for Pfizer Inc.
When was the last downgrade for Pfizer (PFE)?
The last downgrade for Pfizer Inc happened on March 22, 2024 when Argus Research changed their price target from N/A to N/A for Pfizer Inc.
When is the next analyst rating going to be posted or updated for Pfizer (PFE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Pfizer (PFE) correct?
While ratings are subjective and will change, the latest Pfizer (PFE) rating was a reiterated with a price target of $0.00 to $45.00. The current price Pfizer (PFE) is trading at is $25.93, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.